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ABSTRACT
Objective: The aims of this study were to investigate the comparative pharmacodynamics effect of methylprednisolone (MP) innovator, MP branded 
generic, and MP generic products to the serum concentration of annexin A1 (AnxA1).
Methods: It was conducted by two-way crossover design in male rabbits. AnxA1 was measured at 0, 0.5, 1, 2, 3, 5, 7, and 9 h after the administration of 
the drugs. The peak concentration (Cmax), the time at which the peak concentration was achieved (Tmax), and the area under the plasma concentration-
time curve (AUC) were also determined.
Results: The highest concentration and widest AUC of AnxA1 were obtained in MP innovator drug. MP innovator and branded generic reaches the 
peak time (Tmax) at the third 3rd h, while the MP generic reaches the peak time at the 5th h. The results showed that there was no significant difference 
in the serum concentration of AnxA1 between MP tablets after analyzed with a one-way analysis of variance.
Conclusion: It could be concluded that the innovator drug of MP tablet gave the same effect on the serum concentration of AnxA1 than its generic 
counterparts, but an onset of action MP innovator and branded generic is faster than the generic product.
Keywords: Annexin A1, Branded generic, Generic, Innovator drug, Methylprednisolone.
INTRODUCTION
The research on the topic of branded and generic drug comparison 
always provides an interesting perspective among pharmacy 
stakeholders. A one-sided assertion from drug manufacturers about 
the equivalent quality of generic drugs with the innovator products 
raises the pros and cons in the community, including the health-care 
providers. The uses of generic drugs, despite varying, are still very 
popular across the globe. Generic drug prescriptions in the United 
States are counted 89% and cause only 26% of the total drug cost of 
the country [1]. In the United Kingdom, the uses of generic drugs were 
counted 83%. Nonetheless, this number is reported to vary widely 
among European countries not only in the number of uses but also in 
terms of price and market share [2]. In addition, the generic drugs are 
only prescribed in 15% of all prescriptions in Italy [3].
The use of generic drugs as the substitutes for branded drugs has been 
widely recognized in developed countries as an effort to reduce the 
costs of health care [4]. In Indonesia, generic drug use has been stated in 
the Health Ministry Regulation No. HK.02.02/MENKES/068/I/2010 in 
2010. In this decree, the government obliged hospitals and government 
health service facilities to provide, prescribe, and use generic drugs [5].
The existing studies on the comparative quality of branded and generic 
drugs showed different results. The study was conducted by Brown 
et al. who compared that the use of branded and generic drugs of 
alendronate in osteoporosis found a lower efficacy of generic drugs 
as compared to branded products [6]. Another comparative study on 
amoxicillin conducted by Del Tacca et al. found that the generic product 
was not bioequivalent to its innovator product [7]. In addition, Garg 
et al. reported that the incidence of acute adverse effects of the branded 
drug zoledronic acid was only 35.06%, and it is lower than a generic 
product that reached 55.88% [8]. However, some contrary results have 
also been reported. Diaz et al. who conducted an in vitro comparative 
antimicrobial activity of vancomycin with different brands revealed that 
there was no significant difference between their potencies [9]. Similar 
results were also obtained by Cooper-Dehoff and Elliott who compared 
patent and generic drugs of some blood pressure lowering agents that 
included beta-blockers, diuretics, and calcium antagonists [10]. Some 
other studies on clopidogrel and candesartan tablets also reported 
bioequivalence between their patent and generic products [11,12].
Methylprednisolone (MP) is a corticosteroid anti-inflammatory drug 
classified to glucocorticoid. This drug is commonly used to treat many 
different conditions such as skin problems, allergic reactions, arthritis, 
lupus, and other disorders [13]. In Indonesia, the generic products for 
MP can be priced 10 times cheaper than the innovator drug (Medrol®, 
produced by Pfizer). This disparity brings a big question on the quality 
and bioequivalence of drugs, in general, not only to consumers but also 
to the health-care practitioners [14,15].
The bioequivalence study between innovator and generic drugs 
is mostly conducted by investigating the pharmacokinetic profile 
of the drug molecules in the circulatory system [16,17]. Another 
approach that can be useful to compare their quality is by involving 
the pharmacodynamics aspect of the drug. For MP, we hypothesized 
that the serum concentration of annexin A1 (AnxA1) would be a good 
indicator for such purpose. AnxA1 is an anti-inflammatory protein 
that is stimulated by MP and considered as the target molecule of 
corticosteroids in inhibiting the formation of eicosanoids. This protein 
is exposed to cells and tissues treated with glucocorticoids as a result of 
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their pharmacodynamics process. Moreover, it has been found to mimic 
the action of glucocorticoids in some in vitro and in vivo systems [18,19]. 
Further investigation and a comparative study of innovator-generic 
drugs that consider the pharmacodynamics aspect for MP have not 
been reported yet. Based on that situation, this study was conducted 
to compare the pharmacodynamics effect of innovator, branded, and 
generic drugs of MP tablets to the serum concentration of AnxA1.
METHODS
Time and place
The research was conducted in October 2017–December 2017. The 
treatment to the rabbit, taking a sample of blood, and serum making 
were conducted at Serology and Immunology Laboratory, Faculty 
of Pharmacy, Andalas University. Serum testing with enzyme-linked 
immunosorbent assay (ELISA) kit was conducted at Biomedical 
Laboratory, Faculty of Medicine, Andalas University.
Drugs and chemicals
Branded generic and generic tablets of MP were purchased from a local 
pharmacy, while the innovator drug (Medrol®) was a product of Pfizer 
(Jakarta, Indonesia). Distilled water and ethanol 70% were purchased 
from Bratachem (Jakarta, Indonesia). Rabbit AnxA1 ELISA kit (Cat. No 
E0122Ra) was purchased from BT-Lab (Shanghai, China). All materials 
were used as received.
Animal preparation and drug administration
Six male New Zealand white rabbits aged 6 months and weighed 2.7 kg 
were acclimatized under normal laboratory condition for 1 week in 
12/12 light-dark cycle provided standard fed and drinking water ad 
libitum. The rabbits were divided into three groups receiving three 
different MP tablets: MP innovator (Medrol®), MP branded generic, and 
MP generic in the dose of 4 mg (history of the drugs is presented in 
Table 1). Each animal received all three drugs with a 1-week washout 
period (Table 2). The blood sampling was taken through the orbital vein 
in 0, 0.5, 1, 2, 3, 5, 7, and 9 h after the treatment. These specimens were 
centrifuged at 3000 rpm for 20 min. All serums obtained were stored at 
−20°C for further analysis.
AnxA1 determination
The serum concentration of AnxA1 was determined from a total of 144 
serum samples using ELISA. The absorbance was detected at λ 450 nm 
(BioRad Laboratories, CA, USA). In addition, the peak concentration 
(Cmax), the time at which the peak concentration is achieved (Tmax), and 
the area under the plasma concentration-time curve (AUC) were also 
calculated.
Ethical clearance
All of the ethical clearance protocols of this study were approved by 
the Ethics Committee from the Faculty of Medicine, Andalas University 
No. 338/KEP/FK/2017 (October 2, 2017).
Data analysis
The comparative analysis was conducted using one-way analysis of 
variance (ANOVA) MP innovator as the control. It was analyzed with 
Statistical Package for the Social Sciences (SPSS) for Windows (IBM, 
New York, USA).
RESULTS AND DISCUSSION
The bioequivalence study is very crucial to compare two products 
with the same active pharmaceutical ingredient and the same dosage 
form which are bioequivalent despite different formulations. This 
bioequivalence is a good indicator to represent the therapeutic 
equivalence of both products in terms of efficacy and tolerability [10]. 
The good result of the bioequivalence study may allow the manufacturer 
to waive the in vivo study according to the waiver policy of the 
Biopharmaceutics Classification System [20]. However, further in vivo 
studies in experimental animals are, sometimes, required to follow up 
the comparative in vitro dissolution tests. Many physiological factors are 
likely to interfere with the fate of the drugs in the body. These include 
their transit time in the gastrointestinal tract before reaching their sites 
of absorption and their residence time as well, their stability in the 
luminal fluid, and the first pass effect that may alter the metabolism of 
the drug [21].
The comparative pharmacodynamics effect between innovator and 
generic products of MP tablets in the present study was investigated 
in vivo. This in vivo model was considered to emulate better 
pharmacokinetics circumstances in the human body as compared 
with only in vitro dissolution profile. To investigate and compare 
the pharmacodynamics effect of MP products, we used the serum 
concentration of AnxA1, a protein that plays a role in the resolution of 
inflammation, as the biochemical parameter of the drugs’ performance. 
In addition, some parameters such as peak concentration (Cmax), time 
(Tmax), and AUC of this protein were explored.
AnxA1, previously known as lipocortin-1, is a protein regulated by 
glucocorticoids that inhibit the activity of phospholipase A2. This 
protein is also reported to inhibit the cyclooxygenase-2 expression 
and, thus, blocks the production of prostaglandins and other pro-
inflammatory mediators. AnxA1 is considered as an effector molecule 
in the mechanism of action of the anti-inflammation effect of steroid 
drugs [22-24]. In addition, AnxA1 is also believed to be responsible 
for the regulation of the immune system. Furthermore, this protein 
may be potential for the therapeutic target and biomarker in several 
diseases, including cancer and neurodegenerative disorders [25]. The 
glucocorticoid drugs such as MP exhibit their pharmacodynamics effect 
through several inflammatory pathways. One of their mechanisms of 
action is by inducing and activating AnxA1 [26]. Since this protein plays 
a major role in the biochemical process of inflammatory activity of the 
corticosteroid drugs, the fate of this molecule in the circulatory system 
is a reliable parameter to determine the performance of the drug.
Based on Table 3, the concentration of AnxA1 of each drug is 
15.57±0.61 ng/ml, 14.59±0.31 ng/ml, and 14.48±0.11 ng/ml. The 
higher concentration that consists of the drug could give the stronger 
Table 1: Animal grouping and treatment sequence
Group Treatment of MP tablet*
Round 1 Round 2 Round 3
1 MP innovator MP branded 
generic
MP generic
2 MP branded 
generic
MP generic MP innovator
3 MP generic MP innovator MP branded 
generic
*Each treatment round was undertaken with 1-week washout period. 
MP: Methylprednisolone
Table 2: History of selected MP tablets
Type of MP tablet Batch number Expiration date Price per tablet (USD)* Percentage price differential with the innovator
MP innovator 940C8 March 19 0.37 -
MP branded generic TPF36346 May 20 0.19 50
MP generic ITPL00845 October 18 0.04 10
*Converted from IDR to USD. MP: Methylprednisolone
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effect as an anti-inflammatory. The result of ANOVA showed on Table 4 
refers that there are no significant differences of serum concentration 
AnxA1 between innovator drug, branded generic drug, and generic 
drug.
Fig. 1 shows a better effect of innovator product of MP tablet as 
compared with its generic products to the serum concentration of 
AnxA1. The trend of serum concentration of AnxA1 during 9 h of 
observation showed a similar baseline before the administration of MP 
tablets. A clear distinction starts to appear after an hour of observation, 
in which MP innovator shows higher AnxA1 concentration reached in a 
faster period than that in generic products.
The MP of innovator drug showed the same peak time as the MP of 
branded generic drug which reaches the peak time at the 3rd h, while the 
MP of the generic drug reaches the peak time at the 5th h. The difference 
of innovator Tmax MP with generic means a slightly late peak effect of 
drugs. This is also one of the triggers of controversy in the community 
and health professionals with a statement that we often hear that the 
effects of generic drugs are slower to appear than the innovator. This 
Tmax profile can actually answer the controversy. The delay in Tmax 
is actually quite vital if it occurs in life-saving drugs as well as other 
drugs that require fast effects. It is happening because of the quality 
of raw materials, physicochemical properties, and the process of drugs 
manufacturing that could affect the phase.
The overall performance of solid dosage forms, for example, tablets in 
the living tissue depends on the quality of the raw materials [27]. The 
quality is not only influenced by the active pharmaceutical ingredients 
but also by the inactive substances called excipients. The pharmaceutical 
excipients in tablets may include fillers, binders, and disintegrants. 
Inconsistency in fillers, for instance, may trigger the variability in 
dosages. Meanwhile, binders play an important role in the formation 
of granules with good flow properties and tablet compression [28]. 
Variation in the composition of these excipients that present among 
drug products may result in different biopharmaceutical process before 
the absorption of active molecules. In addition, some excipients in the 
formulation are also reported to alter the activity of intestinal transport 
proteins and thus can influence the absorption of the drug molecules. 
Therefore, the pharmaceutical excipients can alter the bioavailability 
and, in turn, the pharmacological effect of the drugs [29].
According to the US Food and Drug Administration, a generic drug 
product is “one that is comparable to an innovator drug product in 
dosage form, strength, route of administration, quality, performance 
characteristics, and intended use [30].” The definition and classification 
of the generic pharmaceutical products are reported to be different 
across the globe, contrary with the innovator drugs that are unvaryingly 
interpreted as drugs produced for the 1st time by the patent holders 
that receive first approval. In Indonesia, for example, the generic drugs 
discriminate into two different types: Branded generic and official 
generic. Branded generic drugs are those sold under trademarked 
names given by the manufacturers, while the official generic drugs are 
those sold under the generic names of the drugs with a special logo on 
the drug packages. A special regulation from the government is applied 
to this official generic drug. Thus, the term “generic drugs” in Indonesia, 
and in the present study as well, refer to not only the official generic 
but also to branded drugs other than the innovator products. As a 
consequence, this may contribute to a variation in the National Drug 
Policy for pharmaceutical manufacturers, especially when submitting 
a new application for their generic products [31]. Therefore, this 
disparity may contribute to the varying performance of the generic 
drugs, especially when compared to the innovator product.
The innovator drug is often believed to exhibit better quality than 
the generic products, as the generic drugs are thought to have lower 
performance. These perceptions are very common in both consumers 
and health-care practitioners, including pharmacists. This is 
predominantly due to limited and wrong information about the generic 
drugs. Unfortunately, this perception causes an impact on the attitude 
of society, both health-care practitioners and consumers, concerning 
the use of generic drug products [15,32,33]. The low acceptance of 
the patients to receive generic products after using the branded drugs 
is also reported [34]. However, this phenomenon can, sometimes, be 
justified since many studies have confirmed significant differences in 
terms of pharmacokinetic profile or pharmacological effect between 
branded and generic drugs [7,35]. The low quality of the generic drugs 
is reported to attenuate not only the efficacy of the drug but also their 
tolerability and safety that may lead to hospital admission [36,37].
It is plausible that a number of limitations in the present study 
are worth considering to not generalize the findings, especially in 
comparing the overall quality of innovator versus generic drugs. First, 
the study investigated only three different MP tablets representing 
three classes of drug classification concerning the brand-generic 
issue. There was no description of the pharmaceutical ingredients 
of the formulations, including the composition of the excipients. In 
addition, the determination of serum concentration of AnxA1 as the 
sole biochemical parameter might not necessarily represent the whole 
quality of the drugs, especially its efficacy. At last, the pharmacological 
effect of the drug, which is in this case to reduce the inflammation, 
was not investigated. Nevertheless, the claim about the equivalent 
performance between innovator, branded, and generic drugs should 
be addressed carefully and responsibly. The regulators are encouraged 
to appropriately maintain the criteria to evaluate the bioequivalence 
studies in the approval of generic drug formulations to guarantee the 
therapeutic equivalence to their innovator products [16].
Fig. 1: The trend of serum concentration of annexin A1 during 
9 h of observation after the administration of methylprednisolone 
tablets (n=144)
Table 3: Comparative parameters of AnxA1 between innovator 







Cmax (ng/ml) 15.56±0.61 14.59±0.31 14.48±0.11
Tmax (h) 3 3 5
AUC (ng*h/ml) 111.88 108.06 103.21
Cmax: The peak concentration; Tmax: The time at which Cmax is achieved; AUC: Area 
under the plasma concentration-time curve; n=144. AnxA1: Annexin A1, 
MP: Methylprednisolone
Table 4: The result of the ANOVA test of AnxA1 between 
innovator drug of MP and its generic tablets (n=48)
Annexin Sum of square df Mean2 F Significant
Between groups 7.139 2 3.570 1.123 0.334
Within groups 143.087 45 3.180
Total 150.226 47
ANOVA: Analysis of variance, AnxA1: Annexin A1, MP: Methylprednisolone
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CONCLUSION
The study concludes that the innovator drug of MP exhibits a 
significantly higher serum concentration of AnxA1 as compared with its 
branded generic and generic tablets. The comparative profile of AnxA1 
shows that the innovator drug demonstrates higher Cmax, faster Tmax, 
and larger AUC than its generic counterparts. The study suggests that 
the innovator drug of MP is likely to produce the same pharmacological 
effect than its generic products.
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